Korea Plans Breakthrough System To Encourage Innovation
Executive Summary
Following up on its May announcement of a conditional approval scheme to shorten R&D and approval periods, and aiming to ensure the prompt and stable supply of life-saving drugs, South Korea is planning a new law on breakthrough therapies and for drugs for public health crises.
You may also be interested in...
2016 Review: Despite Political Woes, Korea Pro-Pharma Policies Stay Intact
2016 has been full of shock and despair in South Korea’s political scene. But when it comes to the country’s biopharma policy, the year has seen fewer surprising or dramatic events.
Korea To Limit Olmutinib Usage, Monitor All Patients
After distributing safety letters on several cases of serious adverse skin reactions that occurred during the clinical development of Hanmi’s olmutinib, South Korean authorities have decided to limit the EGFR inhibitor to consenting patients and are closely monitoring its use.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.